EUVIMEDEUVIMED entdecken
Open Access

Subtype-selective positron emission tomography imaging of poly ADP-ribose polymerase-1 binding in non-human primates, healthy volunteers, and patients with glioblastoma using [11C]AZ14193391

Zsolt Cselényi, Aurelija Jucaite, Giuseppe Stragliotto, Jiri Bartek, Peter Johnström, Andy Pike, Miguel A Cortés González, Antonia Högnäsbacka, Kenneth Dahl, Avipsa Ghosh, Jeffrey W Johannes, Anna D Staniszewska und 14 weitere

Neuro-Oncology · 2026

DOI: 10.1093/neuonc/noaf290 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, 2026. Verfasst von Zsolt Cselényi und 25 weiteren Autor:innen. Beteiligte Einrichtung: PET Science Centre at Karolinska Institutet, Precision Medicine and Biosamples, AstraZeneca, Oncology R&D, Stockholm, Sweden. Hauptthemen laut MEDLINE: Positron-Emission Tomography, Glioblastoma, Poly (ADP-Ribose) Polymerase-1, Brain Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: AstraZeneca, Knut and Alice Wallenberg Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Poly ADP-ribose polymerase-1 (PARP1) is a key enzyme in DNA damage repair and an established target for cancer drug treatment. Although the emergence of non-invasive imaging of PARP using positron emission tomography (PET) has opened new opportunities in cancer diagnosis and drug development, subtype selective imaging of the enzyme, and particularly in brain, remains an unmet need.

Methods

The potent and selective novel PARP inhibitor AZ14193391 was labeled with carbon-11 and evaluated as a candidate PET radioligand for PARP1 through a series of translational in vitro and in vivo molecular imaging studies. These studies encompassed PET in non-human primates, healthy volunteers, and patients with glioblastoma.

Results

Robust radioligand binding to PARP1 was observed in the healthy non-human primate and human brain both in vitro and in vivo. Elevated tumor binding with high contrast was also demonstrated in patients with glioblastoma.

Conclusions

The novel PET radioligand, [11C]AZ14193391 enables subtype selective imaging of PARP1 binding. Its ability to image this protein in the human brain paves the way for accelerated research, diagnosis and drug development in neuro-oncology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron-Emission TomographyGlioblastomaPoly (ADP-Ribose) Polymerase-1Brain NeoplasmsRadiopharmaceuticalsHumansAnimalsCarbon RadioisotopesPoly(ADP-ribose) Polymerase InhibitorsHealthy VolunteersMaleFemaleMiddle AgedAdultAged

Stichwörter der Autor:innen

PARP1PETbraincancerglioblastoma

Substanzen

Poly (ADP-Ribose) Polymerase-1Carbon RadioisotopesCarbon-11Poly(ADP-ribose) Polymerase InhibitorsPARP1 protein, humanRadiopharmaceuticals

Autor:innen und Institutionen

  • PET Science Centre at Karolinska Institutet, Precision Medicine and Biosamples, AstraZeneca, Oncology R&D, Stockholm, Sweden.
  • Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
  • Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
  • DMPK, Oncology R&D, AstraZeneca, Cambridge, UK.
  • Chemistry, Oncology R&D, Waltham.
  • Bioscience, Oncology R&D, AstraZeneca, Cambridge, UK.

Förderung

  • AstraZeneca
  • Knut and Alice Wallenberg Foundation

Zitieren

APA

Cselényi, Z., Jucaite, A., Stragliotto, G., Bartek, J., Johnström, P., Pike, A., Cortés González, M. A., Högnäsbacka, A., Dahl, K., Ghosh, A., Johannes, J. W., Staniszewska, A. D., Leo, E., Hamerlik, P., Davies, B., Cosulich, S., Swales, J., Lawrence, R., Squatrito, M., …, & Schou, M. (2026). Subtype-selective positron emission tomography imaging of poly ADP-ribose polymerase-1 binding in non-human primates, healthy volunteers, and patients with glioblastoma using [11C]AZ14193391. Neuro-Oncology. https://doi.org/10.1093/neuonc/noaf290

Vancouver

Cselényi Z, Jucaite A, Stragliotto G, Bartek J, Johnström P, Pike A, et al. Subtype-selective positron emission tomography imaging of poly ADP-ribose polymerase-1 binding in non-human primates, healthy volunteers, and patients with glioblastoma using [11C]AZ14193391. Neuro-Oncology. 2026. doi:10.1093/neuonc/noaf290

BibTeX
@article{Cselnyi2026,
  author = {Cselényi, Zsolt and Jucaite, Aurelija and Stragliotto, Giuseppe and Bartek, Jiri and Johnström, Peter and Pike, Andy and Cortés González, Miguel A and Högnäsbacka, Antonia and Dahl, Kenneth and Ghosh, Avipsa and Johannes, Jeffrey W and Staniszewska, Anna D and Leo, Elisabetta and Hamerlik, Petra and Davies, Barry and Cosulich, Sabina and Swales, John and Lawrence, Rachel and Squatrito, Massimo and Mueller, Nancy Kathryn and Khani, Yasir and Sousa, Vasco C and Stenkrona, Per and Halldin, Christer and Farde, Lars and Schou, Magnus},
  title = {Subtype-selective positron emission tomography imaging of poly ADP-ribose polymerase-1 binding in non-human primates, healthy volunteers, and patients with glioblastoma using [11C]AZ14193391},
  journal = {Neuro-Oncology},
  year = {2026},
  doi = {10.1093/neuonc/noaf290}
}
Kostenlos starten →